Ascelia Pharma AB (publ) (STO:ACE)

Market Cap	509.35M
Revenue (ttm)	n/a
Net Income (ttm)	-85.07M
Shares Out	116.03M
EPS (ttm)	-1.22
PE Ratio	n/a
Forward PE	41.49
Dividend	n/a
Ex-Dividend Date	n/a

Volume	888,680
Average Volume	1,115,748
Open	4.340
Previous Close	4.340
Day's Range	4.335 - 4.540
52-Week Range	2.000 - 9.700
Beta	1.05
RSI	54.85
Earnings Date	Aug 21, 2025

About Ascelia Pharma AB

Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headq...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 11
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ACE